ProfessorNick Pavlakis

Assessing the prognostic and predictive impact of co-mutations in EGFR mutant NSCLC.

Investigating chemoresistance in BRAF-mutant colorectal cancer

Investigating resistance to tyrosine kinase inhibitor therapy in ALK gene rearranged non-small cell lung cancer- from bedside to bench and back

Positron Emission Tomography as a biomarker in neuroendocrine neoplasms

PRCRT for Advanced GEP-NENs: A Multidimensional Value Assessment

Predictors of treatment response and prognosis in neuroendocrine tumours – understanding the optimal treatment algorithm in a complex treatment landscape

The clinical significance of tumour heterogeneity in HER2-altered non-small cell lung cancer (NSCLC)

The identification and evaluation of predictive and prognostic biomarkers in order to personalise treatment pathways for patients diagnosed with pancreatic cancer.

The impact of CDKN2A/B deletions in IDH-mutant astrocytomas

The role of co-mutations in clinical outcomes in KRAS mutant non small cell lung cancer.

The role of co-mutations in clinical outcomes in KRAS mutant non small cell lung cancer.